The Soft Tissue Sarcoma therapeutics market is anticipated to evolve immensely in the coming years owing to the increased number of STS cases and the launch of emerging therapies in the market. Some of the key players involved in the development of novel drugs includes Arog Pharmaceuticals/Pfizer, Philogen S.p.A., Adaptimmune, and BioAtla.
“Soft Tissue Sarcoma (STS) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Soft Tissue Sarcoma Market.
The Soft Tissue Sarcoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Soft Tissue Sarcoma (STS) Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for the treatment of Soft Tissue Sarcoma and the aggregate therapies developed by major pharma companies.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Soft Tissue Sarcoma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Infusion
Intra-arterial
Intradermal
Intralesional
Intratumoral
Intravenous
Oral
Parenteral
Subcutaneous
Molecule Type
Products have been categorized under various Molecule types, such as
Antibody
Antibody-drug conjugate
Cell therapy
Gene therapy
Immunotherapy
Nanoparticle
Peptide
Recombinant fusion protein
Small molecule
Mechanism of Action of the Emerging Pipeline Therapies
Antibody-dependent cell cytotoxicity
BRD9 protein degraders
Bromodomain and extraterminal domain protein inhibitors
Immunostimulants
DNA intercalators
Angiogenesis inhibitors
Fibroblast growth factor receptor antagonists
Learn How the Ongoing Clinical & Commercial Activities will Affect the Soft Tissue Sarcoma Therapeutic Segment @
https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight
Soft Tissue Sarcoma (STS) Therapeutics Landscape
There are approx. 130+ key companies developing therapies for Soft Tissue Sarcoma. Currently, Philogen is leading the therapeutics market with its Soft Tissue Sarcoma drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Soft Tissue Sarcoma (STS) Therapeutics Market Include:
Advenchen Laboratories, Aadi, Adaptimmune, AGC Biologics, Agenus, Amgen, Apexigen, AROG Pharmaceuticals, AstraZeneca, Atara Biotherapeutics, Athenex, AVEO Pharmaceuticals, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharma France, Clovis Oncology, CytRx, Daiichi Sankyo, Eli Lilly and Company, EMD Serono, Epizyme, Exelixis, Gem Pharmaceuticals, Genor Biopharma, GlaxoSmithKline, Gradalis, Incyte Corporation, Iovance Biotherapeutics, Jiangsu Hengrui Medicine, KaryoPharm Therapeutics, Loxo Oncology, Lytix Biopharma, MedImmune, Merck, Mirati Therapeutics, Morphotek (Eisai), Nanobiotix, NantCell, NantPharma, Novartis, Pfizer, PharmaMar, Philogen, Qbiotics, Roche Pharma AG, Sanofi, Taiho Pharmaceuticals, Tracon Pharmaceuticals, VasGene Therapeutics, and others.
Soft Tissue Sarcoma (STS) Emerging and Marketed Drugs Covered in the Report Include:
ADP-A2M4: Adaptimmune
AL3818: Advenchen Laboratories
BA3021: BioAtla
Crenolanib: Arog Pharmaceuticals
Durvalumab: AstraZeneca
Fibromun: Philagen S.P.A.
GPX-150: Monopar Therapeutics
L19 TNF: Philogen
Lenvatinib: Merck sharp & Dohme Corp.
LTX-315: Lytix Biopharma
NBTXR3: Nanobiotix
Nintedanib: Boehringer Ingelheim
Nivolumab: Bristol Myers Squibb
Yondelis (Trabectedin): Janssen Research & Development, LLC/Pharma Mar
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Soft Tissue Sarcoma Current Treatment Patterns
4. Soft Tissue Sarcoma – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Soft Tissue Sarcoma Late Stage Products (Phase-III)
7. Soft Tissue Sarcoma Mid-Stage Products (Phase-II)
8. Soft Tissue Sarcoma Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Soft Tissue Sarcoma Discontinued Products
13. Soft Tissue Sarcoma Product Profiles
14. Key Companies in the Soft Tissue Sarcoma Market
15. Key Products in the Soft Tissue Sarcoma Therapeutics Segment
16. Dormant and Discontinued Products
17. Soft Tissue Sarcoma Unmet Needs
18. Soft Tissue Sarcoma Future Perspectives
19. Soft Tissue Sarcoma Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Services and Solutions
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
